Antithrombin alfa 1,750unit powder for solution for infusion vials
Antithrombin Alfa is a recombinant antithrombin , an anticoagulant, that is used for the prevention of thromboembolic events in patients that have hereditary deficiency of antithrombin in high risk situations.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Antithrombin alfa
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Clinical guidelines and formulary information
British National Formulary
Antithrombin alfa
Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & product information
Official product databases and supply status monitoring
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
156 found
Half-life
11.6 h
Mechanism
Antithrombin is the main inhibitor of thrombin and Factor Xa , the serine proteases involved in blood coagulation.
Food interactions
1 warning
Human targets
2 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
Half-life
11.6 h
50IU/kg: 11.6 h
100IU/kg: 17.7 h
Protein binding
Volume of distribution
126.2 ml
50IU/kg: 126.2 ml/kg
100IU/kg: 156.1 ml/kg
Vd in hereditary deficient pregnant women in high risk situations had increased Vd of 14.3L.
Metabolism
Elimination
Clearance
9.6 ml
50IU/kg: 9.6 ml/hr/kg
100IU/kg: 7.2 ml/hr/kg
Cl in hereditary deficient pregnant women in high risk situations had increased Cl of 1.38L/h.…
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 641 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
50IU/kg: 11.6 h
100IU/kg: 17.7 h
50IU/kg: 126.2 ml/kg
100IU/kg: 156.1 ml/kg
Vd in hereditary deficient pregnant women in high risk situations had increased Vd of 14.3L.
50IU/kg: 9.6 ml/hr/kg
100IU/kg: 7.2 ml/hr/kg
Cl in hereditary deficient pregnant women in high risk situations had increased Cl of 1.38L/h.
Proteins and enzymes this drug interacts with in the body
PMID:2019570 PMID:21976677
Triggers the production of pro-inflammatory cytokines, such as MCP-1/CCL2 and IL8/CXCL8, in endothelial cells PMID:30568593 PMID:9780208
PMID:22409427
Factor Xa activates pro-inflammatory signaling pathways in a protease-activated receptor (PAR)-dependent manner .
PMID:24041930 PMID:30568593 PMID:34831181 PMID:18202198
Up-regulates expression of protease-activated receptors (PARs) F2R, F2RL1 and F2RL2 in dermal microvascular endothelial cells .
PMID:35738824
Triggers the production of pro-inflammatory cytokines, such as MCP-1/CCL2 and IL6, in cardiac fibroblasts and umbilical vein endothelial cells in PAR-1/F2R-dependent manner .
PMID:30568593 PMID:34831181
Triggers the production of pro-inflammatory cytokines, such as MCP-1/CCL2, IL6, TNF-alpha/TNF, IL-1beta/IL1B, IL8/CXCL8 and IL18, in endothelial cells and atrial tissues .
PMID:24041930 PMID:35738824 PMID:9780208
Induces expression of adhesion molecules, such as ICAM1, VCAM1 and SELE, in endothelial cells and atrial tissues .
PMID:24041930 PMID:35738824 PMID:9780208
Increases expression of phosphorylated ERK1/2 in dermal microvascular endothelial cells and atrial tissues .
PMID:24041930 PMID:35738824
Triggers activation of the transcription factor NF-kappa-B in dermal microvascular endothelial cells and atrial tissues .
PMID:24041930 PMID:35738824
Activates pro-inflammatory and pro-fibrotic responses in dermal fibroblasts and enhances wound healing probably via PAR-2/F2RL1-dependent mechanism .
PMID:18202198
Activates barrier protective signaling responses in endothelial cells in PAR-2/F2RL1-dependent manner; the activity depends on the cleavage of PAR-2/F2RL1 by factor Xa .
PMID:22409427
Up-regulates expression of plasminogen activator inhibitor 1 (SERPINE1) in atrial tissues PMID:24041930
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Antithrombin Alfa
Matched from: Antithrombin alfa
Additional database identifiers
HUGO Gene Nomenclature Committee (HGNC)
HGNC:3535
GenAtlas
F2
GeneCards
F2
GenBank Gene Database
M17262
GenBank Protein Database
339641
Guide to Pharmacology
2362
UniProt Accession
THRB_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:3528
GenAtlas
F10
GeneCards
F10
GenBank Gene Database
K03194
GenBank Protein Database
182841
Guide to Pharmacology
2359
UniProt Accession
FA10_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications: